- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00260559
Outcomes After Esophagectomy With a Focus on Minimally Invasive Esophagectomy and Quality of Life
February 15, 2024 updated by: James Luketich, University of Pittsburgh
To assess short and long term outcomes after minimally invasive esophagectomy compared to open esophagectomy.
To compare both standard outcome measures as well as patient derived outcome measures, in particular, quality of life (QOL).
To look at the applicability of this QOL instrument to this patient group.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Detailed Description
Assess short and long term outcomes after minimally invasive esophagectomy(MIE) compared to open esophagectomy.
Measure standard observer derived outcomes such as morbidity, mortality, tumor recurrence and also patient derived outcomes, in particular quality of life (QOL) using the MOS SF36 questionnaire.
Evaluate whether the SF36 will accurately reflect pre and postoperative changes in clinical status in this patient group.Compare the results of this global QOL instrument (SF 36) to disease specific scales of dysphagia and reflux.
Assess the impact of adjuvant or neoadjuvant therapy on QOL in this patient group and determine if any advantages of MIE can be demonstrated.
Study Type
Observational
Enrollment (Estimated)
3500
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Julie A Ward, BSN
- Phone Number: 412-647-8583
- Email: wardj@upmc.edu
Study Locations
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, United States, 15232
- Recruiting
- UPMC - Hillman Cancer Center
-
Contact:
- Julie A. Ward, BSN
- Phone Number: 412-647-8583
- Email: wardj@upmc.edu
-
Pittsburgh, Pennsylvania, United States, 15213
- Recruiting
- University of Pittsburgh Medical Center - Department of Cardiothoracic Surgery
-
Sub-Investigator:
- Arjun Pennathur, MD
-
Sub-Investigator:
- Matthew Schuchert, MD
-
Contact:
- Julie A. Ward, BSN
- Phone Number: 412-647-8583
- Email: wardj@upmc.edu
-
Principal Investigator:
- James D. Luketich, MD
-
Sub-Investigator:
- Neil A. Christie, MD
-
Sub-Investigator:
- Manisha Shende, MD
-
Sub-Investigator:
- Lawrence Crist, MD
-
Sub-Investigator:
- Ryan Levy, MD
-
Sub-Investigator:
- Omar Awais, DO
-
Sub-Investigator:
- Kevin McGrath, MD
-
Sub-Investigator:
- Angela Gallagher, CRNP
-
Sub-Investigator:
- Rajeev Dhupar, MD
-
Sub-Investigator:
- Inderpal Sarkaria, MD
-
Sub-Investigator:
- Nicholas Baker, MD
-
Sub-Investigator:
- William Gooding
-
Sub-Investigator:
- Daniel Neto, MD
-
Sub-Investigator:
- Tadeusz Witek, MD
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Sampling Method
Non-Probability Sample
Study Population
Patients seeking surgical resection of their esophagus at the University of Pittsburgh Medical Center.
Description
Inclusion Criteria:
- Patients scheduled for MIE (Minimally Invasive Esophagectomy)
- Patients scheduled for open esophagectomy
- Signed informed consent
Exclusion Criteria:
- Patients who are unable to comprehend or complete the QOL instruments.
- Patients less than 18 years of age.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Observational Models: Case-Only
- Time Perspectives: Prospective
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change from baseline in SF36 Quality of Life Questionnaire at 4 month postoperative
Time Frame: Baseline and 4 month postoperative
|
The SF36 is an eight dimension Quality of Life Measurement.
It provides two main Component scores, Physical Component Summary (PCS) and the Mental Component Summary (MCS).
It includes 8 scales or sub-scores: Physical function (PF), role physical (RP), Bodily pain (BP), general health (GH), vitality (VT), social functioning (SF), role emotional (RE), and mental health (MG).
Each scale contributes a different amount to the component scores, which are calculated by a special algorithm that is licensed by Optum.
The Component and sub-scales have a minimum of 0 and a maximum of 100.
The higher the score represent the higher quality of life/less disability.
|
Baseline and 4 month postoperative
|
Change from baseline in SF36 Quality of Life Questionnaire at 6 month postoperative
Time Frame: Baseline and 6 month postoperative
|
The SF36 is an eight dimension Quality of Life Measurement.
It provides two main Component scores, Physical Component Summary (PCS) and the Mental Component Summary (MCS).
It includes 8 scales or sub-scores: Physical function (PF), role physical (RP), Bodily pain (BP), general health (GH), vitality (VT), social functioning (SF), role emotional (RE), and mental health (MG).
Each scale contributes a different amount to the component scores, which are calculated by a special algorithm that is licensed by Optum.
The Component and sub-scales have a minimum of 0 and a maximum of 100.
The higher the score represent the higher quality of life/less disability.
|
Baseline and 6 month postoperative
|
Change from baseline in SF36 Quality of Life Questionnaire at 12 month postoperative
Time Frame: Baseline and 12 month postoperative
|
The SF36 is an eight dimension Quality of Life Measurement.
It provides two main Component scores, Physical Component Summary (PCS) and the Mental Component Summary (MCS).
It includes 8 scales or sub-scores: Physical function (PF), role physical (RP), Bodily pain (BP), general health (GH), vitality (VT), social functioning (SF), role emotional (RE), and mental health (MG).
Each scale contributes a different amount to the component scores, which are calculated by a special algorithm that is licensed by Optum.
The Component and sub-scales have a minimum of 0 and a maximum of 100.
The higher the score represent the higher quality of life/less disability.
|
Baseline and 12 month postoperative
|
Change from baseline in SF36 Quality of Life Questionnaire at 18 month
Time Frame: Baseline and 18 month postoperative
|
The SF36 is an eight dimension Quality of Life Measurement.
It provides two main Component scores, Physical Component Summary (PCS) and the Mental Component Summary (MCS).
It includes 8 scales or sub-scores: Physical function (PF), role physical (RP), Bodily pain (BP), general health (GH), vitality (VT), social functioning (SF), role emotional (RE), and mental health (MG).
Each scale contributes a different amount to the component scores, which are calculated by a special algorithm that is licensed by Optum.
The Component and sub-scales have a minimum of 0 and a maximum of 100.
The higher the score represent the higher quality of life/less disability.
|
Baseline and 18 month postoperative
|
Change from baseline in SF36 Quality of Life Questionnaire at 24 month
Time Frame: Baseline and 24 month postoperative
|
The SF36 is an eight dimension Quality of Life Measurement.
It provides two main Component scores, Physical Component Summary (PCS) and the Mental Component Summary (MCS).
It includes 8 scales or sub-scores: Physical function (PF), role physical (RP), Bodily pain (BP), general health (GH), vitality (VT), social functioning (SF), role emotional (RE), and mental health (MG).
Each scale contributes a different amount to the component scores, which are calculated by a special algorithm that is licensed by Optum.
The Component and sub-scales have a minimum of 0 and a maximum of 100.
The higher the score represent the higher quality of life/less disability.
|
Baseline and 24 month postoperative
|
Change from baseline in SF36 Quality of Life Questionnaire at 30 month
Time Frame: Baseline and 30 month postoperative
|
The SF36 is an eight dimension Quality of Life Measurement.
It provides two main Component scores, Physical Component Summary (PCS) and the Mental Component Summary (MCS).
It includes 8 scales or sub-scores: Physical function (PF), role physical (RP), Bodily pain (BP), general health (GH), vitality (VT), social functioning (SF), role emotional (RE), and mental health (MG).
Each scale contributes a different amount to the component scores, which are calculated by a special algorithm that is licensed by Optum.
The Component and sub-scales have a minimum of 0 and a maximum of 100.
The higher the score represent the higher quality of life/less disability.
|
Baseline and 30 month postoperative
|
Change from baseline in SF36 Quality of Life Questionnaire at 36 month
Time Frame: Baseline and 36 month postoperative
|
The SF36 is an eight dimension Quality of Life Measurement.
It provides two main Component scores, Physical Component Summary (PCS) and the Mental Component Summary (MCS).
It includes 8 scales or sub-scores: Physical function (PF), role physical (RP), Bodily pain (BP), general health (GH), vitality (VT), social functioning (SF), role emotional (RE), and mental health (MG).
Each scale contributes a different amount to the component scores, which are calculated by a special algorithm that is licensed by Optum.
The Component and sub-scales have a minimum of 0 and a maximum of 100.
The higher the score represent the higher quality of life/less disability.
|
Baseline and 36 month postoperative
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: James D Luketich, MD, UPMC - Department of Cardiothoracic Surgery
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
May 1, 1999
Primary Completion (Estimated)
December 1, 2050
Study Completion (Estimated)
December 1, 2050
Study Registration Dates
First Submitted
November 28, 2005
First Submitted That Met QC Criteria
November 28, 2005
First Posted (Estimated)
December 1, 2005
Study Record Updates
Last Update Posted (Actual)
February 20, 2024
Last Update Submitted That Met QC Criteria
February 15, 2024
Last Verified
February 1, 2024
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- STUDY20040382
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Esophageal Cancer
-
OHSU Knight Cancer InstituteOregon Health and Science UniversityWithdrawnStage IIB Esophageal Cancer AJCC v7 | Stage III Esophageal Cancer AJCC v7 | Stage IIIA Esophageal Cancer AJCC v7 | Stage IIIB Esophageal Cancer AJCC v7 | Stage IIIC Esophageal Cancer AJCC v7
-
National Cancer Institute (NCI)NRG OncologyCompletedEsophageal Adenocarcinoma | Gastroesophageal Junction Adenocarcinoma | Stage IIA Esophageal Cancer AJCC v7 | Stage IIB Esophageal Cancer AJCC v7 | Stage IIIA Esophageal Cancer AJCC v7 | Stage IIIB Esophageal Cancer AJCC v7 | Stage IB Esophageal Cancer AJCC v7United States
-
AIO-Studien-gGmbHBristol-Myers SquibbCompletedEsophageal Cancer | Gastrooesophageal Cancer | Oesophageal Cancer | GastroEsophageal Cancer | Esophageal Cancers NOS | Oesophageal Cancer Metastatic | Esophageal Cancer Metastatic | Oesophageal Cancer NosGermany
-
University of Wisconsin, MadisonActive, not recruitingResectable Esophageal Cancer | GastroEsophageal CancerUnited States
-
Tianjin Medical University Cancer Institute and...Sun Yat-sen University; Cancer Institute and Hospital, Chinese Academy of Medical... and other collaboratorsNot yet recruitingStage III Esophageal Cancer | Stage II Esophageal Cancer
-
Tianjin Medical University Cancer Institute and...UnknownStage III Esophageal Cancer | Stage II Esophageal CancerChina
-
Cancer Institute and Hospital, Chinese Academy...Tianjin Medical University Cancer Institute and Hospital; Sichuan Cancer Hospital...UnknownEsophageal Neoplasm | Esophageal Cancer TNM Staging Primary Tumor (T) T3 | Esophageal Cancer TNM Staging Primary Tumor (T) T2 | Esophageal Cancer TNM Staging Regional Lymph Nodes (N) N0 | Esophageal Cancer TNM Staging Distal Metastasis (M) M0China
-
Academisch Medisch Centrum - Universiteit van Amsterdam...UMC UtrechtCompletedEsophageal Cancer, Stage II | Esophageal Cancer Stage IIINetherlands
-
Tianjin Medical University Cancer Institute and...The First Affiliated Hospital with Nanjing Medical University; The First Affiliated... and other collaboratorsUnknownEsophageal Cancer Stage III | Esophageal Cancer Stage IIBChina
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)CompletedGastroesophageal Junction Adenocarcinoma | Stage IIA Esophageal Cancer AJCC v7 | Stage IIB Esophageal Cancer AJCC v7 | Stage IIIA Esophageal Cancer AJCC v7 | Stage IIIB Esophageal Cancer AJCC v7 | Stage IIIC Esophageal Cancer AJCC v7 | Malignant Neoplasm of the Cervical Esophagus | Malignant Neoplasm...United States
Clinical Trials on Questionnaires
-
Memorial Sloan Kettering Cancer CenterNational Cancer Institute (NCI); National Institutes of Health (NIH)Completed
-
Sun Yat-sen UniversityNot yet recruiting
-
Direction Centrale du Service de Santé des ArméesCompleted
-
Assistance Publique - Hôpitaux de ParisRecruitingIntensive Care Unit Syndrome | Pediatric Post-intensive Care SyndromeFrance
-
University Hospital, GrenobleUniversity Grenoble AlpsNot yet recruitingChildhood Cancer | Adapted Physical ActivityFrance
-
M.D. Anderson Cancer CenterCompletedAdvanced Cancer | Malignant Neoplasms of Independent (Primary) Multiple SitesUnited States
-
The University of Hong KongCompleted
-
Centre Hospitalier Universitaire DijonCompleted
-
UNC Lineberger Comprehensive Cancer CenterCompletedBreast Cancer | MetastasisUnited States
-
M.D. Anderson Cancer CenterTerminatedSkin CancerUnited States